GlassScriptPhysician profile
Charles V Casale
NPI 1811074636
$7,491.92
in general payments reported to CMS, 2019-2025
17 companies · $1,720 in 2025
The $1,720 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $122 · 2021: $167 · 2022: $1,277 · 2023: $1,933 · 2024: $1,605 · 2025: $1,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,227 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,227.07 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,571.46 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Janssen Biotech, INC. | $922.41 | 2020-2025 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $611.42 | 2019-2025 | Tremfya, Stelara |
| E.R. Squibb & Sons, L.L.C. | $498.98 | 2022-2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $450.73 | 2023 | Rebyota |
| Celgene Corporation | $421.22 | 2023-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $324.30 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $287.58 | 2021-2025 | Entyvio |
| Lilly USA, LLC | $252.82 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $249.85 | 2022-2025 | Epclusa, Livdelzi |
| Boston Scientific Corporation | $154.50 | 2022-2023 | Hydratome Rx 44, Agile Esophageal, Habib Endohpb |
| Regeneron Pharmaceuticals, INC. | $150.00 | 2025 | Dupixent |
| Madrigal Pharmaceuticals | $145.45 | 2025 | Rezdiffra |
| Allergan, INC. | $144.19 | 2019-2020 | |
| Pfizer INC. | $133.67 | 2019-2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dova Pharmaceuticals | $125.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $48.34 | 2023 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Casale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.